Silkworm pupa powder for mild to moderate Alzheimer's disease
Part of Brain & nervous system, Mental health clinical trials.
This trial tests whether taking a silkworm pupa powder supplement can improve memory and thinking in people with mild to moderate Alzheimer's disease. You'd take the powder by mouth daily, and researchers will monitor your progress over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with Alzheimer's disease, and it should be in the early or middle stage (mild to moderate).
- A blood test or PET scan must show signs of Alzheimer's-related brain changes (amyloid and tau proteins).
- You should be between 50 and 90 years old.
- If you already take Alzheimer's medications, they must have been at the same dose for at least 3 months. Not taking any such medication is also fine.
- You need a caregiver or family member who can reliably help you throughout the study.
- You must be willing to give blood, stool, and urine samples for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a powder made from silkworm pupae can help improve memory and thinking in people with Alzheimer's disease. It is for people with mild to severe Alzheimer's who have clear signs of the disease in their blood or brain scans.
This trial tests whether a dietary supplement made from silkworm pupa powder can improve nutrition in people with Alzheimer's disease. It looks at weight, nutrition risk, and daily living skills over time.
This study tests whether taking a special powder made from silkworm pupae (a natural insect product) can help improve the nutritional health of people with Alzheimer's disease. If you are a caregiver or patient, this might help if you are concerned about eating well or maintaining strength.
This trial tests whether acupuncture can improve symptoms in people with Alzheimer’s disease. You may qualify if you have memory and thinking changes consistent with Alzheimer’s and meet imaging and brain-scan score requirements.
This trial tests a special supplement combination designed to support brain energy use in people with Alzheimer's. It aims to see if the supplement can help slow cognitive decline.
This study tests if a medicine called siponimod, already used for multiple sclerosis, can help people with mild Alzheimer's dementia. You will take a pill daily and be monitored closely for safety and cognitive changes.
Hear when a new Sarcopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.